开发新的提亚醇衍生物作为具有抗癌和前性活性的VEGFR-2抑制剂
Hazem Elkady1, Walid E Elgammal2, Mohamed M Khalifa1
1Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Archiv der Pharmazie
|July 1, 2025
概括
化合物7b是一种新型的亚二醇衍生物,通过抑制VEGFR-2并诱导亡,对乳腺癌细胞表现出强烈的抗癌活性. 这种化合物是乳腺癌治疗的有希望的候选者.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 血管内皮生长因子受体2 (VEGFR-2) 是癌症治疗的关键标.
- 提亚二醇衍生物代表了一类具有潜在抗癌性质的化合物.
研究的目的:
- 合成和评估基于亚醇的新型衍生物作为VEGFR-2抑制剂和抗癌剂.
- 为了研究最强效的化合物7b在MCF-7乳腺癌细胞中的作用机制.
主要方法:
- 提亚二醇衍生物的合成.
- 针对MCF-7细胞的体外细胞毒性测定.
- 进行VEGFR-2抑制测定.
- 细胞周期分析.
- 亡试验 (附录V/PI染色).
- 对与亡相关的蛋白质 (BAX,Bcl-2,caspases) 的西部斑点分析.
主要成果:
- 与索拉费尼布相比,化合物7b对MCF-7细胞表现出更高的细胞毒性活性 (IC50:6.13μM与7.26μM).
- 化合物7b强烈抑制了VEGFR-2 (IC50: 40.65 nM),表现优于索拉芬尼 (IC50: 53.32 nM).
- 化合物7b诱导了G1细胞周期停止和促进了细胞亡,由BAX/Bcl-2比率的增加和升高的caspase-8和caspase-9水平证明.
结论:
- 化合物7b显示出作为乳腺癌抗癌治疗剂的显著潜力.
- 它的机制涉及VEGFR-2抑制,细胞循环停止和通过内在和外在途径诱导亡.
- 进一步的体内和机械学研究是必要的,以开发化合物7b.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
01:24Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K